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Abstract
A mammalian vesicular neurotransmitter transporter has been expressed in the yeast Saccharomyces cerevisiae. The gene
encoding the rat vesicular monoamine transporter (rVMAT1) was cloned in several expression plasmids. The transporter was
expressed at detectable levels only when short sequences using codons favored by S. cerevisiae were fused preceding the start
of translation of rVMAT1. The scarce expression of the wild-type protein was, most likely, due to the fact that part of the N-
terminus of the protein is encoded by codons not preferred in S. cerevisiae. Furthermore, low growth temperatures increased
rVMAT1 expression and altered its processing. Whereas at 30‡C the protein is not glycosylated, at lower temperatures
(V16‡C) half of the expressed transporters undergo core glycosylation. In addition, under these conditions the levels of
protein expression significantly increase. Using a functional chimeric protein composed by VMAT and the green fluorescent
protein (GFP), it is shown that the punctate pattern of intracellular distribution remains invariable at the different
temperatures. Using a similar fusion sequence, the bovine VMAT isoform 2 (bVMAT2) was also expressed in yeast. The
yeast-expressed bVMAT2 binds [3H]dihydrotetrabenazine ([3H]TBZOH) with the same characteristics found in the native
protein from bovine chromaffin granules. Dodecyl maltoside-solubilized bVMAT2 retains the conformation required for
[3H]TBZOH binding. We exploited the robust binding to follow the transporter during purification assays on a Ni2-
chelating column. In this report we describe for the first time the heterologous expression of a neurotransmitter transporter in
the yeast S. cerevisiae. ß 2001 Elsevier Science B.V. All rights reserved.
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1. Introduction
Vesicular neurotransmitter transporters (VNTs)
are responsible for the transport of classical neuro-
transmitters into synaptic vesicles and storage organ-
elles of secretory cells. Vesicular transport activities
have been described for acetylcholine, glutamate,
Q-aminobutyric acid and glycine [1]. The transport
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of biogenic amines has served as the experimental
paradigm, most likely due to the use of bovine chro-
ma⁄n granules, an abundant source of material with
robust transport activity. Transport of the mono-
amines serotonin, dopamine, norepinephrine, epi-
nephrine, and histamine into storage organelles is
catalyzed by the vesicular monoamine transporter
(VMAT). VMAT has been puri¢ed from chroma⁄n
granules [2^4]. Cloning of VMAT was achieved both
by functional expression [5] and using the expression
cloning approach [6]. The cloned transporter protects
against the toxicity of 1-methyl-4-phenylpyridinium
(MPP), by sequestering it within a vesicular com-
partment. Two isoforms of the transporter have been
identi¢ed: VMAT1 and VMAT2. The isoforms show
a high sequence similarity; yet they di¡er in their
pharmacological pro¢le and a⁄nity to histamine.
Whereas VMAT1 is nearly insensitive to tetrabena-
zine (TBZ) inhibition, VMAT2 is inhibited and binds
TBZ at concentrations in the nanomolar range [7].
The identi¢cation of the genes coding for the trans-
porters allowed the analysis of the role of speci¢c
amino acids in the transporter activity [8^11]. In a
recent study, we examined the importance of glyco-
sylation and characterized a mutation at a conserved
proline residue which a¡ects the folding, localization
and activity of VMAT [12].
To further understand the mechanism of trans-
port, high-resolution structure information is re-
quired. Puri¢cation of proteins from native sources
often requires lengthy and laborious procedures. In
recent years, the use of tags has simpli¢ed puri¢ca-
tion procedures to ‘single-column protocols’. E⁄-
cient expression systems are essential for allowing
the introduction of suitable puri¢cation tags and ren-
der large quantities of functional protein. Several
heterologous expression systems were developed
and are extensively used in modern biochemistry.
Among them, the yeast Saccharomyces cerevisiae,
for which a vast knowledge on its genetics and bio-
chemistry is available, became widely accepted. S.
cerevisiae has already been successfully used for het-
erologous expression and cloning of several mem-
brane proteins. For instance, various plant transport-
ers [13^16], mammalian membrane proteins such as
the human D2S dopamine receptor [17], the P-glyco-
protein [18], the mouse transporter protein (MTP)
[19], etc. We have shown recently, that EmrE, a bac-
terial multidrug transporter, is expressed at high lev-
els in S. cerevisiae conferring resistance to a variety
of toxicants by sequestration into the vacuole [20].
VMAT is unique in that it is an H-substrate anti-
porter that its default localization in mammalian
cells is in storage subcellular organelles such as
synaptic vesicles and chroma⁄n granules. In this re-
port we describe the expression of VMAT in S. ce-
revisiae. We found that the expression of VMAT is
highly dependent on several factors, including the
coding sequence of the amino terminus and growth
temperature. The yeast-expressed bVMAT2 binds
[3H]dihydrotetrabenazine ([3H]TBZOH) with the
characteristics displayed by the native protein. We
exploited the stability of the complex [3H]TBZOH-
bVMAT2 to follow the transporter during puri¢ca-
tion procedures.
2. Materials and methods
2.1. Strains
Bacterial strain Escherichia coli DH5K [21] was
used for propagation of recombinant plasmids. The
S. cerevisiae strains used in this study were: YAE65
(MAT a, ade2^119, ilv1^92, trp5-b, sge1, ura3v5)
and YHE4 (MAT a, ade2^119, ilv1^92, trp5-b,
ura3v5) [22,23] (kindly supplied from C. Senstag,
University of Zurich), BWT-1 (MAT a, his3, lys2,
ura3, leu2, trp1, met10, GAL+) [20], YMTAB
(MAT K, leu2^3, 112, ura3v5, pra1: :HIS3, prb1vV,
GAL+) [17] and SY1 (MAT a, ura3^52, leu2^3,112,
his4^619, sec6^4, GAL [24] a gift of Professor C.
Slayman (Yale University).
2.2. Media
S. cerevisiae strains were grown in standard media.
Complete YPD medium (containing 1% yeast ex-
tract, 2% bactopeptone, and 2% glucose) was used
to grow non-transformed strains. Minimal medium
(SD) (0.17% yeast nitrogen base without amino acids
(Difco), 0.5% ammonium sulfate and 2% glucose or
2% galactose) was supplemented according with the
auxotrophic requirements as described in [25]. Tem-
perature of growth was 30‡C unless indicated other-
wise. Expression under GAL promoter was checked
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either after growth in 2% galactose or after exposing
cells which grew using ra⁄nose, lactate or glucose as
carbon source to 2% galactose for 2, 4, 8 and 24 h.
Yeast cells were transformed using the method of
Elble [26].
2.3. Plasmids
The following yeast-expression vectors were used.
pAD4v is a 2W plasmid, LEU2, with ADH promoter
and terminator [27]. p421 is a 2W plasmid, LEU2,
with PMA1 promoter and terminator [28]. p112 is
a CEN4 plasmid, URA3, with GAL1 and GAL10
promoters [29]. p413Gal is a CEN4 plasmid derived
from p413 [30] with the GAL1 promoter inserted at
the Sal I site. BFG-1 is a 2W plasmid, PGK promoter
and terminator, LEU2; it contains an ATG site for
start of translation, followed by three copies of the
hemagglutinin (HA) epitope [31], see Fig. 1A. Canine
calnexin [32], a generous gift from Dr C. Tate (MRC
Laboratory of Molecular Biology, Cambridge, UK),
was expressed under the GPD promoter of the pG-1
plasmid [33]. SHR3 was expressed using the plasmid
pPL250 from [34] kindly provided by Dr Per Ljung-
dahl (Ludwig Institute for Cancer Research, Swe-
den). For stable transfection of CHO cells, pCIN
plasmid allows for stable transfection of cells based
on selection with neomycin [35].
2.4. Cloning procedures
The cDNA of rVMAT1 was excised from pTMI/
rVMAT1 [8] with EcoRI and XhoI and inserted in
pBluescript KS at the same sites creating an inter-
mediate plasmid pBS/rVMAT1. This plasmid con-
tains the EcoRI site immediately before the ATG
that starts the translation of rVMAT1 and the entire
3P untranslated region (592 bases) [5]. To insert
rVMAT1 in the plasmid pAD4v [27], pBS/rVMAT1
was partially digested with PstI and a fragment
Fig. 1. The codon usage at the amino terminus a¡ects the levels of rVMAT1 expression. (A) The ¢rst 13 amino acids and the coding
sequence is shown in the upper box. Codons preferred by yeast [36] are shown with up-arrows, while seldom-used codons are shown
with inverted triangles. The middle box shows to the short sequence fused to rVMAT1 (lane 5). The lower box (lane 6) shows the lon-
ger sequence fused; the HA-epitope (repeated twice) and the fusion site are highlighted. (B) Total membranes prepared from S. cerevi-
siae transformed with the indicated constructs were separated and immunoblotted using an antibody raised against the C-terminus of
rVMAT1 [5]. Similar amounts of protein were loaded onto the gel.
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containing the coding region of rVMAT1 and the
¢rst 281 bases of the 3P-UTR was used for ligation.
rVMAT1 was inserted at the PstI site of pAD4v and
the orientation was veri¢ed with several restriction
enzymes. In the proper orientation, the ATG which
starts the translation is located 10 bases from the
cloning site. To insert rVMAT1 in p112 [29],
rVMAT1 was excised from pBS/rVMAT1 with Bam-
HI and XhoI and inserted in p112 previously digested
with BamHI and SalI. As a result, the ATG is lo-
cated 26 bases downstream the BamHI site and 70
bases from the 5P-end of the mRNA transcript. A
second intermediate plasmid (pBS/rVMAT1-B) was
constructed by partial digestion of pBS/rVMAT1
with PstI and insertion at the same site of pBlue-
script KS. In pBS/rVMAT1-B the ATG (start of
translation) is located near the XhoI site of the
pBluescript multicloning site. To insert rVMAT1 in
p421 [28], pBS/rVMAT1-B was digested with XhoI
and BamHI and the plasmid with XhoI and BglII.
Accordingly, the ATG is located 50 bases from the
XhoI cloning site. pBS/rVMAT1-B was digested with
SalI and NotI and inserted in p413Gal at the same
sites. In p413Gal/rVMAT1, the ATG is located
50 bases from the SalI site.
All PCR-derived sequences were checked for the
absence of point mutations. The insert from pTMI/
rVMAT1 [8] was digested with XhoI and partially
digested with NcoI, and inserted in BFG-1 at the
same sites; in this construct (BFG-1/rVMAT1) the
translation starts from the ATG within the NcoI
site of BFG-1. In this case, three amino acids en-
coded with codons preferred by yeast; e.g., codons
utilized for highly-expressed endogenous proteins
[36] precede the ¢rst amino acid of rVMAT1. To
create BFG-1/HA-rVMAT1, a PCR product using
oligonucleotides PGK-rVMAT1 and RP2421 (all oli-
gonucleotides sequences are shown in Table 1) was
inserted in frame at the ¢rst BamHI site of BFG-1
(see sequence below and in Fig. 1A). The oligonu-
cleotide used places a BamHI site immediately before
the ATG start of translation of rVMAT1. As a result
rVMAT1 contains additional 24 amino acids at its
amino terminus comprising two copies of the HA
epitope (YPYDVPDYA) [37]. Addition of the six-
histidine tag (His6 tag) at the carboxy terminus of
rVMAT1 was done using PCR with primers PGK-
rVMAT1 and a reverse primer designed for this pur-
pose (RP-His Tag-rVMAT1). This primer introduces
an EcoRI site followed by six histidines immediately
before the stop codon of rVMAT1. Therefore, the
His6 tag tail comprises eight residues: phenylalanine
Table 1
Oligonucleotides used in this investigation
Name Purpose Oligonucleotide sequence
PGK-rVMAT1 Insertion of rVMAT1 in frame
in plasmid BFG-1 at BamHI site
Sense 5P-TTGAATTCGTCGACGGATCCATGCTCCAGGTTGTTC




PGK-bVMAT2 Insertion of rVMAT1 in frame
in plasmid BFG-1 at NotI site
Sense 5P-TATAGAGCTCGCGGCCGCATGGCCCTGAGCGAG
RP-bVMAT2 Inserts EcoRI site before the
stop codon to allow insertion
of the His6 tag engineered for
rVMAT1
Antisense 5P-CCGCTCGAGTTAGAATTCGTCACTTTCAGATTCTTCATCC
RP 2421 Adds restriction sites to 3P-UTR
of rVMAT1 for cloning in
di¡erent vectors
Antisense 5P-CGAGATCTGAATTCCTCGAGATCCATTGTGC
HA-pCIN Allows insertion of 5P-end of
HA-tagged genes in plasmid
pCIN
Sense 5P-CGCTCTAGATCGATCGCGGCCGCCATGGTTGGTTACCCATAC
RP-pCIN Allows insertion of genes bearing
the 3P-UTR of rVMAT1 in
plasmid pCIN
Antisense 5P-GCTGAGATCTGAATTCGCTAGCTCGAGATCCATTGTGC
Start of translation sequence is shown with bold, underlined, italicized letters (ATG).
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and glutamate corresponding to the EcoRI site, and
six histidine of the tag. Similarly, BFG-1/HA-
bVMAT2-His was created after in frame insertion
of the coding region of bVMAT2 at the NotI and
XhoI sites of BFG-1 using primers PGK-bVMAT2
and RP-bVMAT2. This construct was next digested
with EcoRI and XhoI and the His6 tag tail (including
the 3P-UTR of rVMAT1) from plasmid BFG-1/HA-
rVMAT1-His was inserted creating BFG-1/HA-
bVMAT2-His. HA-bVMAT2-His contains 38 addi-
tional amino acids at the amino terminus, accommo-
dating three copies of the HA epitope. The DNA





second and third bold-italicized sequences corre-
spond to the NcoI, BamHI and NotI restriction sites
respectively; the ¢rst ATG is within the NcoI site.
The underlined sequences code for HA epitope. For
more information see Fig. 1A and [37]. HA-
rVMAT1-His was cloned in the pCIN vector using
a PCR product prepared using oligonucleotides HA-
pCIN and RP-pCIN cleaved with NotI and BglII.
The vector pCIN was digested with NotI and BamHI
and ligated creating pCIN/HA-rVMAT1-His. pCIN/
bVMAT2-His was constructed after removing the in-
sert from BFG-1/HA-bVMAT2-His with NotI and
PshAI and reinserting it in pCIN/HA-rVMAT1-His
digested with the same sites (PshAI has a unique
recognition site at the 3P-UTR of rVMAT1). As a
result, bVMAT2-His looses the amino acids added
at the amino terminus but preserves the His6 tag.
The chimeric proteins HA-rVMAT1-GFP and HA-
bVMAT2-GFP were constructed after exchanging
the His6 tag with the gene encoding the green £uo-
rescent protein (GFP, mutant S65T) [38] excised
from pRSETb/GFP with EcoRI and XhoI [39]. The
GFP is, thus, inserted in frame at the EcoRI site.
Canine calnexin (GenBank accession number
X53616) inserted in pBluescript II KS at BamHI/
XbaI sites was excised with SacI and EcoRV,
blunt-ended with mung bean nuclease and reinserted
in pBluescript KS at the EcoRV site creating pBS/
calnexin. The orientation chosen is the one in which
the 5P of calnexin is located near the BamHI site of
the plasmid. Calnexin was removed from pBS/calnex-
in with BamHI and SalI and inserted in pG-1 [33] at
the same sites.
2.5. Preparation of total yeast membranes
The protocols used here were described elsewhere
[20].
2.6. Western blot
Blots were performed as described in [37]. Anti-
body dilutions were as follows: 1:5000 for either
monoclonal antibody against the HA epitope
(12CA5, from Berkeley Antibodies Co., BAbCo,
Berkeley, CA) or polyclonal antibody against C-ter-
minus of rVMAT1 [5]. The antibody against calnexin
(from Stressgen, Victoria, British Columbia, Canada)
was diluted 1:10 000.
2.7. Stable transfection of CHO cells
The protocol was described in [12]. Individual
colonies were isolated and tested for MPP resis-
tance, protein expression and binding of
[3H]TBZOH.
2.8. Preparation of CHO membranes
CHO/bVMAT2-His (this work) or CHO/HA-
rVMAT1-His [37] cells were seeded on 15-cm culture
plates and grown in the presence of 1 mM MPP to
ensure elevated VMAT expression. When cultures
reached the highest con£uence possible (80^90%)
cells were harvested either by addition of 25 mM
Na2EDTA in phosphate-bu¡ered saline (PBS) or
scrapped with a rubber policeman in the presence
of antiproteases [20]. Cells were collected 3000Ug/5
min/4‡C and stored at 370‡C prior to use. Mem-
branes were prepared as follows, the frozen pellet
was rapidly thawed at 37‡C and resuspended in
3 ml of lysis bu¡er (0.3 M sucrose, 10 mM Tris^
Hepes (pH 7.4), 5 mM MgCl2). Cells were disrupted
with 20 strokes of a tight pestle-Dounce glass ho-
mogenizer. After spinning the suspension (3000U
g/5 min/4‡C) supernatant was saved and unbroken
cells were resuspended as before, homogenized and
pelleted again. The supernatants were combined and
subjected to ultracentrifugation (300 000Ug/30 min/
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4‡C), the membranes were resuspended in lysis bu¡er
and used the same day.
2.9. Transient expression in CV-1 cells and
preparation of membranes
The methods used in this work, as well as growth
conditions and protocols, were described in detail in
[12].
2.10. Vacuolar stain with FM4^64
The staining with FM4^64, preparation of slides
and visualization in the confocal microscope were
described in [20]. Z-Sections of HA-rVMAT1-GFP
expressing cells were projected to show the punctate
pattern present in the entire cell. The signal corre-
sponding to the GFP £uorescence is shown in the
green channel, whereas the signal of the FM4^64
£uorescence is shown in the red channel.
2.11. Binding of [3H]TBZOH to membranes
K-[2-3H]Dihydrotetrabenazine was purchased from
American Radiolabeled Chemicals (ARC, St. Louis,
MO). Binding was performed essentially as described
in [40], with minor modi¢cations. In brief, 50^100 Wg
membranes were diluted in 300 Wl of binding bu¡er
(0.3 M sucrose, 10 mM K-Hepes, pH 7.4) containing
3 nM [3H]TBZOH in the absence or presence of ex-
cess tetrabenazine (100 WM). Binding was allowed to
occur at room temperature for 15 min. To stop the
reaction, 4 ml of ice-cold binding bu¡er supple-
mented with 100 WM tetrabenazine were added,
and samples were immediately ¢ltered on a HAWP
¢lter 0.45 Wm pore size (Millipore). Filters were
washed twice with 3 ml of the same solution. For
pH dependence studies membranes were diluted in
ammonium bu¡er (150 mM NH4Cl, 20 mM Mes^
Tris, 5 mM MgCl2, titrated to the indicated pH) in
the presence of 6.6 nM [3H]TBZOH for 30 min at
room temperature. Reactions were stopped with 4 ml
of ice-cold ammonium bu¡er (pH 7.4) supplemented
with 100 WM TBZ and ¢ltered as described earlier.
Scatchard analysis was performed at pH 7.4, with
[3H]TBZOH concentration ranging from 1 to 60
nM. Reactions were stopped after 20 min at room
temperature.
2.12. Puri¢cation of His6-tagged bVMAT2 from yeast
membranes
One to 5 ml HA-bVMAT2-His membranes (10 mg
protein/ml) were ¢rst labeled with [3H]TBZOH as
follows. Membranes were diluted in 10 ml ammo-
nium bu¡er (pH 7.4) containing 20 nM [3H]TBZOH
for 15 min at room temperature. Reactions were
stopped by centrifugation at 400 000Ug/15 min/
4‡C. The pellet was washed with 6 ml ammonium
bu¡er, and membranes were ¢nally resuspended in
2 ml of bu¡er. Solubilization was achieved by step-
wise addition of dodecyl maltoside (DM) and cholate
to ¢nal concentrations of 0.5% and 0.25%, respec-
tively. Suspension was cleared 400 000Ug/15 min/
4‡C, and supernatant was allowed to bind to Ni2-
NTA beads previously equilibrated with the same
bu¡er, in the presence of 30 mM imidazole. Binding
was allowed for 1 h, with rotation in a cold room.
The bead suspension was loaded in a mini-column
and the £owthrough was reloaded three times. The
column was washed ¢ve times with 4 ml of ammo-
nium bu¡er containing 0.08% DM, 0.04% cholate
and 30 mM imidazole. The protein was eluted in
the same bu¡er as above, but supplemented with
200 mM imidazole. Fractions were collected and ra-
dioactivity was assessed by liquid scintillation. In
parallel, speci¢c bVMAT2 presence in the di¡erent
fractions was detected using Western blots as de-
scribed above.
2.13. Binding of [3H]TBZOH to Ni2+-NTA
immobilized transporter
Membranes were diluted in ammonium bu¡er
(150 mM NH4Cl, 1 mM MgCl2, 10 mM Tris^Hepes,
pH 7.4) spun at 400 000Ug/15 min/4‡C and resus-
pended in 1 ml of the same bu¡er. Membrane solu-
bilization and binding to Ni2-NTA beads was per-
formed as described above. The beads were spun 30 s
in a microfuge, washed twice with 1 ml ammonium
bu¡er containing 0.08% DM and 0.04% cholate, and
divided into aliquots. The beads were washed once
with bu¡ered solutions (10 mM Mes^Tris) and al-
lowed to bind [3H]TBZOH (6 nM) at the indicated
pH for 30 min at 4‡C with rotation. The binding was
measured in triplicate and non-speci¢c binding was
measured in the presence of 125 WM TBZ. The bind-
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ing was stopped after centrifuging the suspension for
30 s. The beads were washed once with 1 ml ammo-
nium bu¡er containing 0.08% DM and 0.04% chol-
ate, and radioactivity was assessed by liquid scintil-
lation. Since the binding of the transporter to Ni2-
NTA beads is also pH-dependent, one of the tripli-
cates was used to normalize for the amount of trans-
porter bound to the beads. The protein bound to the
beads was eluted with 200 mM imidazole. The elu-
ates were mixed with protein sample bu¡er and sep-
arated on an SDS^PAGE gel as described above.
HA-bVMAT2-His was detected using immunoblots.
Quantitation of the blots was achieved using the
MacBas 2.0 software. Results of radioactivity were
normalized according to the quantitation results tak-
en the binding at pH 7.4 as control (100% of bind-
ing).
3. Results
3.1. The codons chosen at the N-terminus of rVMAT1
are important for expression
Expression of foreign proteins, specially membrane
proteins may interfere with the delicate balance of
cellular processes and therefore can have deleterious
e¡ects on cell viability. For this reason rVMAT1 was
¢rst cloned in an array of expression plasmids that
allowed us to control the expression. p112 [29] and
p413Gal (derived from [30]) are centromeric plasmids
in which the expression is under the inducible GAL1
promoter. Regulation of expression is tight; induc-
tion of expression is achieved only after removal of
glucose from the medium and upon addition of ga-
lactose. On the other hand, plasmids p421 [28] and
pAD4v [27] are multicopy plasmids equipped with
strong constitutive promoters. After completion of
plasmid construction, yeast strain BWT-1 was trans-
formed with p421/rVMAT1, pAD4v/rVMAT1, p112/
rVMAT1 and p413Gal/rVMAT1. To study the ex-
pression of rVMAT1, yeast transformants carrying
p421/rVMAT1 or pAD4v/rVMAT1 were grown on
glucose media. Cells carrying the rVMAT1 under
the GAL1 promoter (p112/rVMAT1 and p413Gal/
rVMAT1) were grown directly on 2% galactose, or
¢rst grown on glucose, ra⁄nose or acetate, and then
the carbon source was replaced by 2% galactose. Ex-
pression of rVMAT1 was assessed using a polyclonal
antibody directed against the carboxy terminus of
the transporter [5]. No immunoreactive material
was detected in membranes prepared from cells car-
rying the rVMAT1 gene cloned in the above expres-
sion plasmids. A representative Western blot is
shown in Fig. 1B (lanes 1^4). To test whether an
intrinsic determinant, located within the rVMAT1
gene was hampering the expression of the transport-
er, the codon usage of the 5P end of rVMAT1 was
examined. The use of synonymous codons is strongly
biased in the yeast S. cerevisiae. Following the clon-
ing of the ¢rst glycolytic enzymes, it became clear
that yeast evolution changed gene codons in a way
where major codons replaced minor codons in highly
expressed proteins, and vice versa [36]. In addition, it
was shown that replacing an increasing number of
major codons with synonymous minor ones at the
5P end of the coding sequence caused a dramatic
decline of the expression level of phosphoglycerate
kinase [41]. Examination of the codon usage at the
5P end of rVMAT1 reveals a trend of minor codons
rarely used in S. cerevisiae [36,42]. The ¢rst 13 co-
dons encoding the N-terminus include at least six
that are seldom utilized in yeast for highly expressed
proteins (see Fig. 1A, upper box). To test the possi-
bility that the codon usage was impeding the expres-
sion of rVMAT1, we fused readily translatable short
sequences before the natural start of translation.
First, we fused a sequence coding four amino acids
using codons favored by yeast (see Fig. 1A, middle
box). This addition notably changed the expression
of rVMAT1, and a single polypeptide with an appar-
ent size of 45 kDa became easily detectable on im-
munoblots (Fig. 1B, lane 5). Following this rationale
a longer sequence of 24 amino acids was fused, cre-
ating HA-rVMAT1. The fused sequence includes two
copies of the hemagglutinin (HA) epitope
(YPYDVPDYA). The longer fusion further in-
creased the level of expression of rVMAT1 by at least
one order of magnitude (see Fig. 1B, lane 6). Impor-
tantly, we found no expression from a BFG-1 plas-
mid bearing the HA-rVMAT1 fusion but lacking the
3P untranslated region (3P-UTR) of rVMAT1 (not
shown). The 3P-UTR probably stabilizes the
mRNA transcript allowing e⁄cient expression.
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3.2. The yeast-expressed rVMAT1 displays the size of
the unglycosylated transporter
Addition of epitopes has potentially deleterious
e¡ect on protein function. We have already shown
that when the tagged transporter is expressed in a
mammalian expression system, it displays identical
kinetic and pharmacological features as the un-
tagged, wild-type protein [12,37]. The yeast-expressed
protein shows an apparent Mr similar to that of the
unglycosylated form of the transporter (45 kDa, Fig.
2A, lanes 1 and 4). The 45 kDa polypeptide detected
above with an antibody against the HA epitope lo-
cated at the N-terminus is not a proteolytic frag-
ment, since the protein detected with an antibody
against the C-terminus displays the same molecular
mass (see Fig. 1A, lane 4). As shown in Fig. 2A, the
size of the yeast-expressed protein (lane 4) corre-
sponds to the size of the unglycosylated mutant (‘Tri-
ple’, lane 3) and to the wild-type protein produced in
presence of tunicamycin in a mammalian system
(lane 4), (see also [12]).
3.3. The expression rVMAT1 is enhanced at low
temperatures
We have shown that glycosylation is not required
for rVMAT1 activity in a mammalian system [12].
The mutant rVMAT1 in which all glycosylation sites
have been mutated away retains the ability to protect
mammalian cells against the toxicity of MPP [12].
Yet, in the case of the yeast-expressed rVMAT1, it
fails to confer resistance to MPP to strains YAE65
and YHE4 which are particularly sensitive to the
toxin [20,22]. In addition, membranes prepared
from yeast expressing rVMAT1 do not catalyze nei-
ther serotonin transport nor reserpine binding (not
shown). It has been suggested that N-linked glycosyl-
ation serves, among other functions, as quality con-
trol device for correct protein folding in the endo-
plasmic reticulum (ER) [43]. rVMAT1 is probably
not glycosylated in yeast because of improper fold-
ing. Since protein folding and stability are often fa-
vored under low temperatures, S. cerevisiae was
grown at di¡erent temperatures and the e¡ect on
the processing of rVMAT1 was investigated. As
shown in Fig. 2B, rVMAT1 expression was highly
in£uenced by the temperature of cultivation. As tem-
Fig. 2. (A) Yeast-expressed rVMAT1 displays the mobility of
the non-glycosylated protein. Membranes were prepared from
Vaccinia-infected CV-1 cells (monkey kidney ¢broblasts) trans-
fected with rVMAT1 (lanes 1 and 2) and bVMAT2 (lane 6). In
both cases the HA epitope was fused to the N-terminus as de-
scribed in Fig. 1. The rVMAT1 protein expressed in the pres-
ence of the glycosylation inhibitor tunicamycin is shown in lane
2. In lane 3, a ‘Triple’ of rVMAT1 devoid of all canonical gly-
cosylation sites is shown [12]. Membranes prepared from S. ce-
revisiae grown at 30‡C expressing rVMAT1 or bVMAT2 are
shown in lanes 4 and 5, respectively. The samples were immu-
noblotted with a monoclonal antibody against the HA epitope.
(B) rVMAT1 undergoes core glycosylation at low growth tem-
peratures. S. cerevisiae was grown at di¡erent temperatures and
the e¡ect on rVMAT1 expression and processing was tested.
Membranes prepared from cells grown at 16‡C, 24‡C, 30‡C and
37‡C were separated on a Laemmli 9% gel and immunoblotted
using a monoclonal antibody against the HA epitope. Note the
increase in the level of expression and the appearance of glyco-
sylated rVMAT1 at low growth temperatures (16‡C, lane 5).
Addition of the ligand reserpine during the growth step did not
in£uence rVMAT1 expression or processing (lane 2). Similar
lack of e¡ect was detected with other substrates of transport:
noradrenaline and serotonin (not shown).
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peratures decreased (24‡C and 16‡C) expression lev-
els signi¢cantly increased. Furthermore, at 16‡C a
large fraction of the expressed rVMAT1 underwent
core glycosylation. As seen in Fig. 2B, lane 5, a dis-
tinct band with an apparent molecular mass of V53
kDa is clearly recognized. This band corresponds to
the core-glycosylated form usually seen using the T7
polymerase/Vaccinia virus expression system (see Fig.
2A, lane 1) [12]. The bands seen at V87 kDa corre-
spond to oligomeric forms of VMAT. Upon treat-
ment with N-glycosidase F (PNGase-F), the band
coinciding with the glycosylated form disappears,
whereas the lower unglycosylated form remains in-
tact (not shown). The results imply that under the
low-temperature conditions the transporter is post-
translationally modi¢ed.
3.4. The intracellular distribution of VMAT is not
altered at di¡erent temperatures
To follow the above ¢ndings, the intracellular dis-
tribution of the transporter at various growth tem-
peratures was tested. For this purpose, a functional
chimera between the tagged rVMAT1 and the green
£uorescent protein was prepared (HA-rVMAT1-
GFP). Notably, the pattern of HA-rVMAT1-GFP
£uorescence distribution was virtually identical at ei-
ther 30‡C or 14‡C (shown in green, Fig. 3, 30‡C or
14‡C). Indicating that although at lower tempera-
tures rVMAT1 undergoes core-glycosylation, the
transporter is still targeted to the same organelle.
The punctate pattern corresponding to the chimeric
transporter is present uniformly in the cell and re-
C
Fig. 3. The intracellular distribution of rVMAT1 remains invar-
iable at the di¡erent growth temperatures. A chimera between
rVMAT1 and the green £uorescent protein (GFP) was prepared
to follow the distribution of the transporter in living cells.
Yeast cells were grown at 30‡C and 16‡C, stained with the vac-
uolar marker FM4-64 and visualized with a confocal micro-
scope. Fluorescence corresponding to the GFP is shown in
green, while that of the FM4-64 dye is shown in red. The pat-
tern of £uorescence of the rVMAT1-GFP chimera resembles the
late-Golgi marker Kex2p [44]. A similar pattern was found for
bVMAT2-GFP (not shown). As a control we expressed GFP
alone using the same fusion sequence. The GFP shows a clear
cytoplasmic distribution (lower panel). The VMAT-GFP chime-
ras are completely functional in a mammalian expression system
(not shown).
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sembles the distribution of the late-Golgi marker
Kex2p [44]. This pattern contrasts to the ring stain-
ing decoration of the vacuolar vital stain of FM4^64
(shown in red) and clearly di¡ers from the cytoplas-
mic pattern found for the wild-type HA-GFP (Fig. 3,
lower panel) or the vacuolar-targeted HA-EmrE-
GFP transporter [20], both proteins expressed using
the same N-terminal fused sequence.
3.5. Simultaneous expression of chaperones and
VMAT
Our manipulations have increased the level of ex-
pression and glycosylation. Yet, the rVMAT1 ex-
pressed in yeast is still incapable of protecting the
yeast cells against MPP, or of catalyzing transport
of monoamines or binding reserpine. To improve the
probability to achieve correct protein maturation we
tested the e¡ect of co-expression of mammalian cal-
nexin (a known chaperone) together with VMAT.
The co-expressed calnexin migrates in SDS^PAGE
as the endogenous calnexin from cell lines CHO,
CV-1 and MDCK cells (not shown). In addition to
calnexin, we co-expressed Shr3p from a high copy-
number plasmid [34]. Shr3p is an ER-resident yeast
chaperonin shown to be essential for packaging of
amino acid permeases into transport vesicles
[34,45,46]. Nonetheless, cells expressing simultane-
ously VMAT, calnexin and Shr3p did not show en-
hanced resistance towards MPP. Membranes pre-
pared from these cells were still unable to bind
reserpine or to accumulate serotonin. We also tested
the addition of substrates and ligands as they were
shown to act as molecular chaperones for otherwise
misfolded proteins [47,48]. Membranes from cells
grown on standard medium supplemented with milli-
molar concentrations of serotonin or noradrenaline
or micromolar concentrations of reserpine did not
induce enhanced VMAT activity or protein matura-
tion (see Fig. 2B, lane 3). Finally, no di¡erences in
rVMAT1 expression were found between cells bear-
ing or lacking the co-expressed chaperones, grown
either at 30‡C, 24‡C or 16‡C (not shown).
3.6. The yeast-expressed bVMAT2 binds
tetrabenazine
None of the above manipulations rendered a pro-
tein capable of transporting serotonin in a proton-
dependent manner. This activity requires proper as-
sembly into a proton impermeable membrane and
may even require speci¢c lipids. Therefore binding
of [3H]dihydrotetrabenazine ([3H]TBZOH), a partial
activity detected even in detergent (see below) was
measured. As already stated, tetrabenazine binds to
and inhibits VMAT2 at nanomolar concentrations
while concentrations as high as 20 WM do not a¡ect
transport mediated by VMAT1 [7]. The gene encod-
ing bVMAT2 [49] was inserted in the plasmid BFG-1
at the NotI site. Since we intended to purify the ex-
pressed protein, a polyhistidine (His6) tag was engi-
neered by PCR at the carboxy terminus, this protein
was also referred to as HA-bVMAT2-His. Taking
into consideration our previous results, the 3P-UTR
of rVMAT1 was included in this construct to stabi-
lize the mRNA transcript and to achieve e⁄cient
expression. The yeast expressed bVMAT2 displays
a mobility similar to the fully functional protein ex-
pressed using the T7 Polymerase/Vaccinia virus ex-
pression system suggesting similar glycosylation lev-
els (see Fig. 2A, lanes 5 and 6). The expression levels
and the degree of glycosylation of bVMAT2 were
much less sensitive to the growth temperature than
those of rVMAT1 (data not shown). As shown in
Fig. 4A, membranes prepared from cells expressing
bVMAT2 (closed bars) but not rVMAT1 (open bars),
display high-a⁄nity [3H]dihydrotetrabenazine bind-
ing. When the speci¢c binding was analyzed using
the method of Scatchard, a linear plot was obtained
suggesting the presence of a single species of binding
sites. The Kd calculated for the yeast-expressed
bVMAT2 was 15.3 nM and the Bmax was 13.7
pmol/mg, whereas the Kd for the CHO-expressed
bVMAT2 was 29.5 nM and the Bmax was 73.2
pmol/mg. The measured constants were in good
agreement with the values found for the native pro-
tein in the literature [40]. From the measured number
of binding sites, we estimate about 15 000^20 000
copies of bVMAT2 per cell. The expression level of
rVMAT1 was in the same order of magnitude, as
estimated from quantitative Western blots. As in
the native protein, [3H]TBZOH binding to the
yeast-expressed bVMAT2 was sensitive to nanomolar
concentrations of ketanserin but barely inhibited by
micromolar concentrations of reserpine, millimolar
concentrations of serotonin or noradrenaline (not
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shown). In addition, the binding did not depend on
an imposed proton gradient as the reactions were
performed in the absence of ATP. The binding of
[3H]TBZOH to chroma⁄n granules shows a distinc-
tive pH dependence [50]. As shown in Fig. 4B (bars),
the binding of [3H]TBZOH to chroma⁄n granules
(gray bars) is low at acidic pH (5.8) and increases
to its maximum at pH 7.4^8.0, whereas at more basic
conditions it begins to decline. An analogous behav-
ior was measured for the yeast expressed bVMAT2
(see Fig. 4B, dark bars). Our results are essentially
the same as found by Scherman and Henry [50], ex-
cept that in our hands binding decreases at alkaline
pH. Based on the results presented here, we conclude
that the binding of tetrabenazine in the yeast-ex-
pressed bVMAT2 resembles that in the native trans-
porter from bovine chroma⁄n granules.
3.7. [3H]TBZOH binding to a detergent-solubilized
immobilized bVMAT2
Recently a convenient assay for high-a⁄nity li-
gand binding in a detergent solubilized transporter
was introduced [51]. This assay takes advantage of
the ability to immobilize His6-tagged proteins on
Ni2-NTA beads. We adapted this assay to assess
TBZOH binding on the detergent-solubilized
bVMAT2 anchored on the metal chelate adsorbent
(Ni2-NTA beads). We found that dodecyl maltoside
(DM) is appropriate for solubilizing bVMAT2 in a
Fig. 4. (A) Binding of [3H]dihydrotetrabenazine to bVMAT2.
Membranes prepared from CHO and S. cerevisiae expressing ei-
ther rVMAT1 or bVMAT2 were tested for [3H]TBZOH binding
as described in Section 2. Binding was performed in triplicate
and allowed for 10 min at room temperature. (B) The solubi-
lized bVMAT2, immobilized on Ni2-NTA beads shows the
same pH dependence of [3H]TBZOH binding as the native pro-
tein from bovine chroma⁄n granules. Bovine chroma⁄n gran-
ules (gray bars) and membranes from yeast-expressing bVMAT2
(black bars) were assayed for [3H]TBZOH binding using bu¡-
ered solutions titrated to di¡erent pHs as described in Section
2. A similar pH-dependence was found for the recombinant
and the native protein. In a separate experiment, membranes
from yeast expressing bVMAT2 were solubilized and allowed to
bind to Ni2-NTA beads as described in Section 2. Beads were
washed and assayed for [3H]TBZOH binding at di¡erent pHs
(open triangles). The amount of binding was normalized ac-
cording to the protein retained at the beads. Control experi-
ments using membranes from non-expressing cells showed no
signi¢cant binding above background (not shown). (C) Puri¢ca-
tion of bVMAT2 using Ni2-NTA beads. The complex
[3H]TBZOH-bVMAT2 was used to follow the bVMAT2 during
the puri¢cation process. Membranes were labeled with
[3H]TBZOH, solubilized, allowed to bind to Ni2-NTA beads,
and mounted on a mini-column. The column was washed sev-
eral times and the protein was eluted with 200 mM imidazole.
The radioactivity of the fractions was assessed using scintilla-
tion counting. The presence of bVMAT2 in the di¡erent frac-
tions was tested using Western blots (middle panel). A similar
gel was prepared and stained with coomassie blue (lower panel).
For experimental details see Section 2.
C
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form that retains high [3H]TBZOH binding activity.
Yeast membranes previously labeled with 15 nM
[3H]TBZOH were solubilized using 0.5% DM (or a
combination of 0.5% DM and 0.25% cholate).
[3H]TBZOH remains associated with the solubilized
bVMAT2 as judged by the fact that the majority of
the radioactivity released to the supernatant could be
subsequently bound to Ni2-NTA beads. Conversely,
it was possible to assay [3H]TBZOH binding on solu-
bilized bVMAT2 and immobilized on Ni2-NTA
beads. The binding was dependent on the presence
of bVMAT2 and could be competed away by excess
of unlabeled tetrabenazine or ketanserin. In agree-
ment with previous ¢ndings [52], increasing concen-
trations of cholate (up to 1.5%) caused the gradual
loss of bound [3H]TBZOH. Also, Triton X-100 was
found deleterious for [3H]TBZOH binding activity
[52]. This e¡ect is reversible since upon exchange
with 0.5% DM the binding activity is recovered. Im-
portantly, the immobilization assay gives an excellent
signal-to-noise ratio since the beads can be washed
several times without loosing signi¢cant counts. To
test whether the immobilized bVMAT2 exhibits the
characteristics of the membrane inserted protein, we
examined also the pH dependence of [3H]TBZOH
binding. The results shown in Fig. 4B (triangles)
demonstrate that the immobilized bVMAT2 reprodu-
ces the pH dependence of [3H]TBZOH of the protein
in the membrane.
3.8. Puri¢cation of the [3H]TBZOH binding activity
To purify rVMAT1 expressed in mammalian cells
we used immobilized metal a⁄nity chromatography
[37]. Using a similar approach that takes advantage
of its robust [3H]TBZOH binding activity we puri¢ed
the yeast expressed bVMAT2. Membranes were ¢rst
labeled with [3H]TBZOH, and then solubilized with
DM and cholate. Since [3H]TBZOH remained bound
after solubilization, it was possible to follow the pro-
tein during the puri¢cation process assessing the ra-
dioactivity associated with the di¡erent fractions (see
Fig. 4C). The radioactivity found in the void volume
and the initial washes of the column, represents
[3H]TBZOH non-speci¢cally bound to proteins or
released upon solubilization. Using immunoblots
some bVMAT2 was also detected in fractions corre-
sponding to non-stringent washes (Fig. 4C, lower
panel wash 1^5). The bulk of the speci¢c
[3H]TBZOH binding activity remained bound to
the beads and was released only in the presence of
200 mM imidazole (see Fig. 4C, elution 1). When the
eluted fractions were resolved on SDS^PAGE and
stained with coomassie blue, a predominant band
with a size of V63 kDa was detected (Fig. 4C lower
panel). A single band with a similar size was specif-
ically identi¢ed by Western blot (see Fig. 4C, middle
panel, elution 1) suggesting that the major band was
bVMAT2.
4. Discussion
Vesicular monoamine transporters (VMATs) are
H-driven antiporters that catalyze the transport of
biogenic amines across membranes of secretory or-
ganelles. The mechanism of transport remains ob-
scure, largely because of the lack of suitable expres-
sion systems which provide large amount of protein
for biochemical and crystallographic characteriza-
tion. High-level expression of functional polytopic
membrane proteins is a di⁄cult task due to the prob-
lems that arise regarding e⁄cient protein folding and
stability. In this report we describe the ¢rst detailed
attempt to express vesicular monoamine transporters
in the yeast S. cerevisiae. After several futile attempts
to express rVMAT1 using the endogenous codon for
initiation of translation, elevated expression was
achieved only after modi¢cation of the codon usage
of the initiation region. Instead of substituting the
hampering codons for the yeast-preferred ones, short
and readily translatable sequences were fused in
frame immediately before the ¢rst methionine of
the protein. As a result a drastic increase in the ex-
pression was obtained. The levels of expression in-
creased together with the length of the fused se-
quence. The use of synonymous codons is strongly
biased in the yeast S. cerevisiae [36]; a major deter-
minant of this bias is the abundance of the di¡erent
tRNA species [53]. Evidently, protein synthesis is
more e⁄cient when the pool of the required tRNAs
is not limiting. Besides, e¡ective translation probably
confers increased stability to the mRNA transcript.
Therefore, preferred codons improve protein expres-
sion and favor mRNA stability.
The 5P-UTR sequences may a¡ect the e⁄ciency of
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protein synthesis. In the case of rVMAT1, the di¡er-
ences in expression levels cannot be explained by this
factor: two plasmids with identical 5P-UTR but vary-
ing only in the fused translated sequences express
rVMAT1 at very di¡erent levels. Furthermore, we
showed that fusion of the longer sequence was su⁄-
cient to procure high expression of bVMAT2 (this
work), the green £uorescent protein (GFP) and the
E. coli multidrug transporter EmrE [20]. Finally, we
also found that apart from the e¡ect of the codon
usage at the N-terminus, the 3P-untranslated region
of rVMAT1 was critical for expression. This region
contains the mammalian polyadenylation signal and
may serve as stabilizing factor for the mRNA tran-
script, therefore promoting e⁄cient expression.
rVMAT1 was expressed at relatively high levels,
yet the size of the protein corresponded to the size
of the non-glycosylated form. Lack of glycosylation
is usually correlated with misfolding of proteins. We
deduced that rVMAT1 is incorrectly folded as no
signi¢cant activity was detected in a variety of assays
that test established traits of the functional trans-
porter. Low cultivation temperatures caused a re-
markable increase in the levels of expression. Fur-
thermore, under these conditions about half of the
expressed rVMAT1 underwent core glycosylation.
This post-translational modi¢cation, not occurring
at 30‡C, indicates that a speci¢c folding event was
accomplished. Yet, additional steps leading towards
genuine conformation are necessary since activity
was still not detected. As judged by chimeras with
the GFP, the intracellular distribution of rVMAT1
(and although not shown also of bVMAT2), re-
mained unchanged either at 30‡C or 14‡C, conditions
at which rVMAT1 undergoes core glycosylation. The
punctate pattern of £uorescence resembles the late-
Golgi compartment. The acquisition of a correct
three-dimensional conformation in the ER is not a
spontaneous, unassisted event. The ER contains a
variety of molecular chaperones and foldases in-
volved in the folding and maturation process [54].
Since the endogenous yeast chaperones may not rec-
ognize mammalian misfolded proteins, we co-ex-
pressed canine calnexin together with VMAT. Cal-
nexin was initially chosen as it was found to be the
chaperone causing the maximal increase in the level
of functional heterologously-expressed plasma-mem-
brane serotonin transporter (SERT) [55]. Although
the yeast-expressed calnexin showed mobility similar
to that of the endogenously expressed mammalian
counterpart, its expression was ine¡ectual regarding
the production of functional rVMAT1 or bVMAT2.
In contrast to rVMAT1, the expression levels of
bVMAT2 were only slightly a¡ected by the growth
temperature.
Using membrane preparations from S. cerevisiae
expressing bVMAT2, it was possible to measure
high-a⁄nity speci¢c dihydrotetrabenazine ([3H]-
TBZOH) binding. The binding properties shown by
the heterologously expressed bVMAT2 were similar
to those found in the native chroma⁄n granule
transporter. Only ketanserin and tetrabenazine com-
pletely abolished [3H]TBZOH binding, whereas ex-
ceedingly high concentrations of reserpine and sub-
strates of transport modestly inhibited the reaction.
In addition, the distinctive pH dependence of
[3H]TBZOH binding known for the native protein
was detected also in the yeast-expressed bVMAT2.
Based on the ability of dodecyl maltoside to solubi-
lize bVMAT2 in a form that retains [3H]TBZOH
binding activity, a novel binding assay was devel-
oped. The assay takes advantage of a poly-histidine
tag engineered at the C-terminus of bVMAT2 and a
metal chelate adsorbent (Ni2-NTA beads). The im-
mobilized bVMAT2 displays the same features of the
membrane protein regarding the a⁄nity to
[3H]TBZOH, the pharmacological pro¢le and the
pH dependence of binding.
It was previously shown that it is possible to use
the Ni2-NTA resin to purify the transporter [37,56].
In this communication we exploited the robust
[3H]TBZOH binding to follow the protein during
the puri¢cation procedure directly assessing the ra-
dioactivity at each fraction. Although a supplemen-
tary chromatographic step is required to obtain pure
preparations of the protein, a notable enrichment is
achieved using a single Ni2-NTA column.
Sievert and collaborators have expressed rVMAT2
using baculovirus-infected insect cells [56]. The ex-
pressed protein display [125I]AZIK (7-azido-8-
[125I]iodoketanserin) and [3H]TBZOH binding activ-
ity, yet no transport activity or reserpine binding
were shown. In our hands rVMAT1 expressed in
this system shows neither of these activities albeit
elevated levels of expression (RY and SS, unpub-
lished observations).
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In this work we developed general strategies for
expression of heterologous proteins in yeast: namely,
fusion to readily translatable sequences having co-
dons preferred by yeast and growth at low temper-
atures. Yet, the results illustrate the di⁄culties to
express fully functional vesicular monoamine trans-
porters perhaps due to the complex folding of these
proteins or the lack unknown essential factors. Strik-
ingly, the native binding site for tetrabenazine and
ketanserin is formed using di¡erent heterologous ex-
pression systems. The results imply that its correct
assembly is less dependent on the folding machinery.
We therefore propose the possibility that the creation
of the binding site demands fewer adjacent domains
within the protein or it is composed by determinants
located within the same region of the polypeptide. In
contrast, the reserpine and substrate binding site re-
quires a more delicate arrangement. This site is di-
rectly a¡ected by the H-electrochemical gradient
since it drives the refolding needed to accelerate the
binding of reserpine and to catalyze the whole trans-
port process.
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